

MANAGEMENT OF RECCURENT BRAIN GLIOMA

Thesis

Submitted for partial fulfillment of MD Degree in
Radiation Oncology & Nuclear Medicine

By

Mohammed Abdel Moneam Mohammed
M.B.B.Ch. & M.Sc.

Supervised by

Prof. Dr.: LAILA FARIS MATTA
Professor of Radiation Oncology & Nuclear Medicine
Faculty of medicine, Ain Shams University

Prof. Dr.: Mamdouh Mohamed Salama
Professor of Neurosurgery
Faculty of medicine, Ain Shams University

Dr.: Amin El-Sayed Ahmed Amin
Assistant professor of Radiation Physics
Faculty of medicine, Ain Shams University

Dr.: Iman Aly Elsharawy
Assistant professor of Radiation Oncology & Nuclear Medicine
Faculty of medicine, Ain Shams University

Dr.: Hatem Mohamed Abd Alla
Assistant professor of Radiation Oncology & Nuclear Medicine
Faculty of medicine, Ain Shams University

**Faculty of medicine
Ain Shams University
(2009)**

Acknowledgement

Acknowledgement

First and for most, thanks are due to ALLAH, to whom I relate any success in achieving any work in my life.

My words stand short of my supreme gratitude and thanks to ***Prof. Dr. LAILA FARIS***, Professor of Radiation Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shames University, for her continuous supervision, valuable guidance, generous encouragement, great support and overall her kindness that gave me and this work the scope to light.

Special thanks are due to ***Prof. Dr. Mamdouh Salama*** Professor of Neurosurgery, Faculty of Medicine, Ain Shames University, for dedicating so much of his precious time and support in preparing this work.

I am also profoundly grateful to ***Dr. Amin El-Sayed***, Assistant Professor of Radiation Physics, Faculty of Medicine, and to, ***Dr. Iman Elsharawy***, ***Dr. Hatem Abd Alla***, Assistant Professors of Radiation Oncology, and Nuclear Medicine, Ain Shames University for their continuous close supervision, support, constant help and fair stimulating remarks throughout this study. Words of thanks are so little for their great help in preparation of this work.

Finally, I wish to thank all members of my family for their continuous help, encouragement and support.

LIST OF APPREVIATIONS

AA: Anaplastic astrocytoma
AGT: Alkylguanine-DNA alkyltransferase.
AIC: Aminoimidazole-4-carboxamide.
AO: Anaplastic oligodendroglioma.
ASUSH: Ain Shams University Specialist Hospital.
ATTL: Autologous tumor-specific T lymphocyte.
AUC: Area under curve.
BBB: Blood brain barrier.
BCM20: Brain Cancer Module.
BCNU: Carmustine.
bFGF: basic fibroblast growth factor.
BID: Twice daily.
BMC: Blood mononuclear cell.
CCNU: Lomustine.
CDK4: cyclin dependant kinase 4.
CPT-11: Irinotecan.
CR: Complete response.
CRT: Conformal radiotherapy.
CTLs: Cytotoxic T-lymphocytes.
CTV: Clinical target volume.
DC: Dendritic cells.
DP: Disease progression.
DVH: Dose Volume Histograms.
EIAEDs: Enzyme-inducing antiepileptic drugs.
EORTC: European Organisation for Research and Treatment of Cancer.
EGFR: Epidermal Growth Factor Receptor.
FasL: Fas ligand.
FP: Fixation point.
FSRT: Fractionated stereotactic radiotherapy.
GBM: Glioblastoma multiforme.
GTV: Gross tumor volume.

HDAC: Histone Deacetylase.
 HDR: High dose rate.
 HIF-1 α : Hypoxia Inducible Factor- 1 α .
 H-FSRT: Hypofractionated stereotactic radiotherapy.
 HR-QOL: Health-related quality of life.
 IGF2: insulin like growth factor 2.
 IL-2: Interleukin-2.
 IOERT: Intraoperative electron radiotherapy.
 KPS: Karnofsky performance Status.
 IMRT: Intensity-modulated radiotherapy.
 LDR: Low dose rate.
 LGG: Low grade glioma.
 LOH: Loss of heterozygosity.
 LQ: Linear quadratic
 LR-RIT: Locoregional radioimmunotherapy.
 MAb: Monoclonal antibody.
 MGMT: Methylguanine-DNA methyltransferase.
 MvEC: Microvascular endothelial cell.
 MMP: Matrix metalloproteinase.
 MMR: Mismatch repair.
 MRS: Magnetic resonance spectroscopy.
 MTIC: 5-(3-methyl-1-triazeno)imidazole-4-carboxamide.
 MTD: Maximum tolerated dose.
 mTOR: Mammalian target of rapamycin.
 NCCN: National Cancer Comprehensive Network.
 OA: Oligoastrocytoma.
 O-2A: Oligodendrocyte type 2 astrocyte.
 OARs: Organ at risks.
 OD: Oligodendroglioma.
 OER: Oxygen enhancement ratio.
 OS: Overall Survival.
 O⁶-BG: O⁶-benzylguanine.
 O⁶-MG: O⁶- Methylguanine.

PARP: Poly-ADP-ribose polymerase.
PCP: Pneumocystis carinii pneumonia.
PCV: procarbazine, lomustine, and vincristine.
PD: prescribed dose.
PET: Positron Emission Tomography.
PFS: Progression free survival.
PDGFR: Platelet derived growth factor receptor.
PDGFR: PDGF receptor.
PlGF: placental growth factor.
PI3K: Phosphoinositol 3-kinase.
Poly-ICLC: Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose.
PR: Partial response.
PTEN: Phosphatase and tensin homolog.
PTV: Planning target volume.
PXA: Pleomorphic xanthoastrocytoma.
QOL: Quality of life.
QLQ-C30: Quality of life questionnaire core-30.
Rb gene: Retinoblastoma gene.
RT: Radiotherapy.
SD: Stable disease.
SDF-1: Stromal cell-derived factor-1.
SGCA: Subependymal Giant Cell Astrocytoma.
SPECT: Single photon emission computed tomography.
SRS: Stereotactic radiosurgery.
TD: Tolerance dose.
TNF: Tumor necrosis factor.
TPS: Treatment planning system.
TSG: Tumor suppressor genes.
TMZ: Temozolomide.
VEGF: Vascular endothelial growth factor.
VEGFR: VEGF receptor.
WHO: World health organization.

LIST OF TABLES

Table Number	Content	Page Number
1	WHO Classification: of tumors of the central nervous system.	12
2	Summary of studies that showed PET accuracy in differentiation between radiation necrosis and recurrence	44
3	The results of the study of Yung et al., 2003.	53
4	Table summarizes the effect of TZM in different recurrent brain gliomas.	58
5	A summary of the standard dosage schedule for TZM in recurrent brain glioma.	62
6	Table showing the side effects associated with gliadel wafer in the study of Westphal et al., 2006.	74
7	Comparison of some pharmacokinetic features of TZM and procarbazine.	75
8	Table summarizes the observations in the study of Yung et al., 2002.	76
9	Table summarizes the toxicity profile of the study of Fine et al., 2000.	77
10	Results of the study of Cloughesy et al., 2008.	90
11	Table summarizing other studies done on bevacizumab and irinotecan in recurrent brain gliomas.	91
12	Classification of targeted therapies in brain glioma.	94
13	Antiangiogenic agents in practice and their targets.	103
14	Clinical, Radiologic, and Pathologic Findings of radiation induced brain injury.	116
15	Factors associated with radiation tolerance.	117
16	Tolerance doses of normal central nervous system tissues to irradiation (after single irradiation course).	118
17	Series of patients with recurrent gliomas treated with stereotactic radiosurgery.	145

18	A series of patients with recurrent gliomas treated with fractionated stereotactic radiotherapy.	147
19	A series of patients with recurrent gliomas treated with H- FSRT.	149
20	Table summaries of studies in patients with recurrent gliomas treated with brachytherapy.	153
21	Comparison between modalities of highly conformal radiation therapy.	155
22	Summaries of studies in patients with recurrent gliomas treated with radio-chemotherapy.	161
23	Summarizes some studies done for reoperation in recurrent glioma.	165
22	The preoperative KPS in the 32 patients included in their study of Eftimov et al., 2007.	237
23	The chemotherapy schedule in our protocol.	184
24	Karnofsky index of performance status.	196
25	FACT/NCCN Brain Symptom Index (FBrSI).	197
26	National cancer institute common toxicity criteria (CTC)- Version 2.0.	200
27 (A)	RTOG acute radiation morbidity scoring criteria.	203
27 (B)	RTOG late Radiation Morbidity Scoring criteria.	204
28	Patients' Characteristics of the 30 patients with recurrent brain glioma enrolled between February 2005, and December 2008.	206
29	Diseases' characteristics of the 30 patients with recurrent brain glioma enrolled between February 2005, and December 2008.	208
30	Main presenting symptoms of 30 patients enrolled in the study.	210
31	Characters of patients who achieved objective response to treatment, or stable disease.	218
32	Relation between age of the 30 patients with recurrent brain glioma and response to treatment.	219
33	Relation between performance state of the 30 patients with recurrent brain glioma and response to treatment.	222
34	Relation between histopathological grade of the 30 patients with recurrent brain glioma and response to treatment.	223
35	Relation between time interval between two radiotherapy courses of the 30 patients with	224

	recurrent brain glioma and response to treatment.	
36	Relation between tumor size of the 30 patients with recurrent brain glioma and response to treatment	227
37	Table showing the Survival results of our current study.	228
38	Relation between patient age of the 30 patients with recurrent brain glioma and the 6 months survival.	232
39	Relation between KPS of the 30 patients with recurrent brain glioma and the 6 months survival.	233
40	Relation between histological type of the tumors of the 30 patients with recurrent brain glioma and the 6 months survival.	234
41	Relation between time interval of the 30 patients with recurrent brain glioma and the 6 months survival.	236
42	Relation between tumor histopathology of the 30 patients with recurrent brain glioma and the QOL score changes.	243
43	Relation between KPS of the 30 patients with recurrent brain glioma and the QOL score changes.	245
44	Relation between response to treatment of the 30 patients with recurrent brain glioma and the QOL score changes.	246
45	Hematological toxicities observed after 125 cycles of TZM given to 30 patients with recurrent brain glioma.	248

LIST OF FIGURES

Figure Number	Content	Page Number
1	Incidence of different brain gliomas at Recurrence.	7
2	Incidence of different brain gliomas at initial diagnosis.	7
3	H&E stain of fibrillary and gemistocytic LGG.	14
4	H& E stain of anaplastic astrocytoma	14
5	H& E stain of GBM.	15
6	H& E Stain of gliosarcoma.	16
7	H& E Stain of WHO grade II oligodendroglioma	17
8	H& E Stain of WHO grade III AO.	17
9	H& E Stain of oligoastrocytoma.	18
10	H&E Stain of WHO grades II and III ependymoma.	19
11	Molecular genetic alterations of different astrocytomas	26
12	Molecular genetic alterations in oligodendrogliomas	27
13	Apoptosis occurs Through Two Main Pathways.	30
14	Schematic representation of immunosuppressive mechanisms associated with malignant gliomas.	33
15	CT perfusion images of a patient with a recurrent GBM in the left parietal lobe.	37
16	MR perfusion images for recurrent GBM in the right parietal lobe with surrounding edema.	40
17	MR spectroscopy of recurrent AA	41
18	MR spectroscopy of recurrent brain glioma	42
19	FDG PET study of recurrent brain glioma,	44
20	Chemical structure and conversion pathway of temozolomide.	52
21	Six-months PFS advantage in Gliadel wafers.	73
22	Comparative efficacy of temozolomide and procarbazine in patients with recurrent GBM.	76
23	Therapeutic opportunities of targeted therapies in brain glioma.	95
24	Antiangiogenic drugs, and their targets.	102
25	Each fractionation factor and its effect.	112

26	Effect of oxygen in cell survival curve.	113
27	Doubling Time for different glioma cells.	124
28	3D-CRT to treat recurrent brain stem glioma.	126
29	3D- CRT Volume definitions.	131
30	Radiotherapy planning cycle (“forward planning”)	132
31	Beam’s eye view, three-dimensional patient model.	133
32	Observer’s view. The sub-volume where all three beams overlap can be identified easily.	134
33	An IMRT plan showing radiation isodose lines curving around the auditory nerves and cochleas.	136
34	Multiple radiation portals, each individually shaped by a multileaf collimator.	139
35	Dose–volume histograms for OARs. in posterior fossa irradiation.	142
36	Before linear accelerator–based SRS, a patient’s head is rigidly fixed on the treatment couch using an invasive stereotactic head frame.	143
37	Gamma Knife treatment planning for the solid parts of the recurrent cystic pilocytic astrocytoma.	144
38	Correlation between the performance state and the treatment (reoperation) outcome in patients with recurrent brain glioma.	176
39	Treatment protocol for our current study.	183
40	DVH showing the expected doses to the target, and various organs at risk for recurrent left parietal LGG reirradiation.	188
41	Posterior temporal lesion treated with two lateral opposing wedged angled fields.	191
42	Main presenting symptoms with % patients in our current study.	210
43	A schematic representation of results of the 30 patients with recurrent brain glioma treated by TZM, and conformal radiotherapy during the period between February 2005 to December 2008 at ASUSH.	212
44	Comparison between patient’s age <60, >60 and the response to treatment.	220
45	Comparison between patient’s age <40, >40 and	221

	the response to treatment.	
46	Relation between performance status and the response to treatment.	222
47	Relation between histopathologic grading and the response to treatment.	224
48	Relation between time interval and the response to treatment.	225
49	Relation between time interval and the response to treatment.	226
50	Relation between tumor size and response to treatment.	227
51	The cumulative PFS of our current study.	229
52	The cumulative OS of our current study	229
53	Six-months PFS of the current study.	230
54	Six-months OS of the current study.	230
55	Correlation between % of patient's age before treatment and 6 months after treatment in the study	232
56	Relation between patients' KPS before treatment and 6 months in correlation with the survival after treatment.	233
57	Relation between patients' tumor histopathology in correlation with the survival before treatment and after 6 months.	235
58	Relation between time interval between 2 radiotherapy courses in correlation with survival before treatment and 6 months after treatment.	237
59	QOL score changes in 30 patients with recurrent brain glioma treated by Temozolomide and conformal radiotherapy during the period between February 2005 to December 2008.	242
60	Relation between % patients showing QOL improvement and histopathologic grading.	244
61	Relation between % patients showing QOL improvement and KPS.	245
62	Relation between % patients showing QOL improvement and response to treatment.	247

INTRODUCTION

Primary intracranial tumors account for 1.4% of all cancers. Malignant gliomas constitute 50-60% of all primary intracranial tumors. **(Wrensch et al., 1999)**

Brain gliomas include astrocytomas [(low grade, anaplastic, and glioblastoma multiforme (GBM)], oligodendrogliomas, ependymomas, and mixed gliomas. **(Kenilworth., 1999)**

Abnormalities in receptor tyrosine kinase pathway and loss of tumor suppressor genes (TSN) are critical factors in the transformation of glial cells into malignant cells. **(Holland E., 2001)**

Following primary treatment, recurrence occurs in approximately 70% of gliomas. **(Hvizdos, Goa., 1999)**

Patients with recurrence usually present with new complaints including headache, nausea, vomiting, personality changes, seizures, and, or focal neurological syndromes. **(Bauman et al., 1996)**

To confirm the diagnosis of recurrence, MRI is very helpful. Re-biopsy is also indicated in some cases. **(Hadani et al., 2001)**

It is extremely important to distinguish tumor recurrence from radiation induced necrotic changes. This can be achieved by Thallium201 SPET, 18Ffluorodeoxyglucose PET, and MR spectroscopy. **(Hazle et al., 1997)**

Treatment of recurrent glioma includes surgical resection, chemotherapy, radiation therapy, and, or novel molecular, and targeted therapies. **(Stephen, Raymond., 2003)**

The main goal of surgery is removal of the enhancing tissues to decrease pressure effect and to provide diagnosis in ambiguous cases. **(Stephen, Raymond., 2003)**

Temozolomide as an imidazotetrazine agent is effective in recurrent glioma. It is associated with a response rate of about 27.5% **(Yung et al., 1999).**

Myelotoxicity (primarily neutropenia and thrombocytopenia) is the major adverse effect of temozolomide observed in number of clinical trials **(Osoba et al., 2000).**

Brain reirradiation seems feasible, and effective. The tolerance of the brain depends on dose per fraction, total dose administered, overall treatment time, time interval between primary treatment and reirradiation, volume of brain irradiated, adjunctive therapies, and other factors. **(Schultheiss et al., 1995) (Veninga et al., 2001)**

A wide variety of radiotherapy (RT) techniques have been used including conventional radiotherapy, 3D- conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), brachytherapy, stereotactic radiosurgery (SRS), fractionated stereotactic radiotherapy (FSRT), and

hypofractionated stereotactic radiotherapy (H-FSRT).

(Veninga et al., 2001)

By 3D-CRT, the entire three- dimensional distribution of radiation to the tumor and normal tissue can be calculated. This tool allows treatment plans to be designed that limit higher doses to affect normal tissue. Additionally, this tool allows additional dose escalation to the tumor. **(Hudes, et al., 1999)**

Temozolomide can be administrated with reirradiation. Such combination is associated with objective responses of about 20%. **(Schonekaes et al., 2002).**

Molecular therapies represent another line of management of recurrent glioma. They include growth factor receptors inhibitors (e.g. imatinib, iressa), antiangiogenic agents (e.g. bevacizumab, thalidomide), and others **(Fine et al., 2003).**

AIM OF THE WORK

This study was done to assess the response rate, survival benefits and toxicity profile of temozolomide, and brain reirradiation by using conformal radiotherapy for the treatment of recurrent brain glioma.

The study included 30 patients with recurrent brain glioma treated in the Oncology Unit, Ain Shams University Specialist Hospital (ASUSH) between February 2005 and December 2008.

Chapter 1

EPIDEMIOLOGY

Malignant brain tumors account for about 1.4 % of all cancers and are responsible for 2.4% of cancer-related deaths. The annual incidence of primary malignant brain tumors is 6.4 per 100,000 populations. **(Jemal et al, 2005)**

Malignant glioma is the most common form of malignant brain tumors. They represent 50% to 60% of all primary brain tumors, and about 0.8% of all malignant tumors in adults. The incidence is 4 per 100.000 populations per year. **(Dillon., 2001)**

In Egypt: although there is no general cancer registry, in the last 3 years; 2006, 2007, 2008, the department of clinical oncology, Ain Shams University received 80 patients with brain glioma (1.4%), of them 56 patients (70%) recurred.

Definition of recurrence:

The term "tumor recurrence" is frequently used synonymously with "tumor progression".

The criteria used to define recurrent brain glioma remain ambiguous due to the following:

First, the infiltrative nature of glioma cells makes it difficult to eliminate microscopic disease despite macroscopic gross-total resection. Studies have shown that glioma recurrence often occurs in the form of local continuous growth within 2 to 3 cm from the border of the original lesion. **(Choucair et al., 1986)**